Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
The early clinical success and subsequent US Food and Drug Administration approval of chimeric antigen receptor (CAR)-T cell therapy for leukemia and lymphoma affirm that engineered T cells can be a powerful treatment for hematologic malignancies. Yet this success has not been replicated in solid tu...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Immuno-Oncology and Technology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590018823000138 |